Physician profile
Nguyen Vu
NPI 1225420938
$2,696.12
in general payments reported to CMS, 2019-2025
22 companies · $436 in 2025
The $436 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $456 · 2022: $407 · 2023: $909 · 2024: $488 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,833.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $605.74 | 2021-2025 | |
| Novo Nordisk INC | $460.58 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $422.46 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $164.15 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $144.10 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $142.58 | 2022 | |
| Corium, LLC | $131.49 | 2023-2024 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.07 | 2023 | Xifaxan |
| Astrazeneca Pharmaceuticals Lp | $98.07 | 2022-2024 | Airsupra, Farxiga |
| Otsuka America Pharmaceutical, INC. | $88.45 | 2022-2025 | Rexulti |
| Glaxosmithkline, LLC. | $70.43 | 2021-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Idorsia Pharmaceuticals US INC | $54.80 | 2023 | Quviviq |
| Amgen INC. | $35.50 | 2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.08 | 2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $22.22 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $21.56 | 2023 | Zio Xt Patch |
| Amarin Pharma, INC. | $19.09 | 2022 | |
| Scynexis, INC. | $18.18 | 2022 | |
| Hologic Sales and Service, LLC | $17.18 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.61 | 2021 | |
| Genentech USA, INC. | $13.00 | 2021 | |
| Phathom Pharmaceuticals, INC. | $8.78 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nguyen Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.